Heatwurx (PCSA) Stock Price, News & Analysis

Company Overview

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Key Stats

• Today's Range: $2.45 to $2.68
• 50-Day Range: $2.24 to $3.18
• 52-Week Range: $1.76 to $19.64
• Volume: 37,721 shs
• Average Volume: 53,742 shs
• Market Capitalization: $7.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Hold

Heatwurx Stock Analysis - MarketRank™

Heatwurx scored higher than 64% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Heatwurx has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Heatwurx has a consensus price target of $25.00, representing about 843.4% upside from its current price of $2.65.

Amount of Analyst Coverage

Heatwurx has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Heatwurx is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Heatwurx is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Heatwurx has a P/B Ratio of 2.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.05% of the float of Heatwurx has been sold short.

Short Interest Ratio / Days to Cover

Heatwurx has a short interest ratio ("days to cover") of 1.88, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Heatwurx has recently increased by 30.34%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Heatwurx does not currently pay a dividend.

Dividend Growth

Heatwurx does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.00

News Sentiment

Heatwurx has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Heatwurx this week, compared to 1 article on an average week.

Search Interest

Only 6 people have searched for PCSA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

1 people have added Heatwurx to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.4 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

7 insiders have purchased shares of Heatwurx in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $106,406.00 in company stock, which represents 1.4601% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Heatwurx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $106,406.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

2.40% of the stock of Heatwurx is held by insiders.

Percentage Held by Institutions

91.93% of the stock of Heatwurx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/06/2025
• Today: 5/25/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PCSA
• CIK: 1533743
• Web: www.processapharmaceuticals.com
• Phone: (443) 776-3133
• Fax: 443-288-4420
• Employees: 20
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Heatwurx: $25.00
• High Price Target: $25.00
• Low Price Target: $25.00
• Potential Upside/Downside: +843.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.56 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -281.31%
• Return on Assets: -200.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.98
• Quick Ratio: 0.98

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.92 per share
• Price / Book: 2.88

Miscellaneous

• Outstanding Shares: 2,750,000
• Free Float: 2,684,000
• Market Cap: $7.29 million
• Optionable: Not Optionable
• Beta: 1.01